TNXP · CIK 0001430306 · operating
Tonix Pharmaceuticals is a commercial-stage biotechnology company developing therapeutics for central nervous system (CNS) and immunology disorders. The company's marketed products include TONMYA (cyclobenzaprine HCl sublingual tablets) for fibromyalgia treatment, and two migraine therapies, Zembrace SymTouch and Tosymra, which treat acute migraine with or without aura in adults. These products generate the company's primary revenue streams.
The development pipeline spans multiple therapeutic areas. TNX-102 SL, the active ingredient in TONMYA, is being evaluated for fibromyalgia management and several CNS indications including posttraumatic stress disorder, Alzheimer's disease, and alcohol use disorder. Additional programs include TNX-1300 for cocaine intoxication, TNX-1900 (intranasal potentiated oxytocin) for binge eating disorder and obesity, TNX-1500 (monoclonal antibody) for transplant rejection and autoimmune conditions, TNX-801 for smallpox and mpox prevention, TNX-1700 for gastric and colorectal cancers, and TNX-2900 for Prader-Willi syndrome. The company maintains collaboration agreements with Bilthoven Biologicals and Makana Therapeutics to advance specific programs.
Tonix operates with approximately 81 full-time employees and is headquartered in Chatham, New Jersey. The company is listed on Nasdaq and incorporated in Nevada.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-176.60 | $-176.60 | -2478.1% | |
| 2023 | $-6.85 | $-6.85 | -109.5% | |
| 2022 | $-3.27 | $-3.27 | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — | |
| 2016 | — | — | — | |
| 2015 | — | — | — | |
| 2014 | — | — | — | |
| 2013 | — | — | — | |
| 2012 | — | — | — | |
| 2011 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-18 | 0001999371-25-002786 | SEC ↗ |
| 2023-12-31 | 2024-04-01 | 0001999371-24-004297 | SEC ↗ |
| 2022-12-31 | 2023-03-13 | 0001387131-23-003377 | SEC ↗ |
| 2021-12-31 | 2022-03-14 | 0001387131-22-003640 | SEC ↗ |
| 2020-12-31 | 2021-03-15 | 0001387131-21-003550 | SEC ↗ |
| 2019-12-31 | 2020-03-24 | 0001387131-20-003189 | SEC ↗ |
| 2018-12-31 | 2019-03-18 | 0001387131-19-001980 | SEC ↗ |
| 2017-12-31 | 2018-03-09 | 0001615774-18-001762 | SEC ↗ |
| 2016-12-31 | 2017-04-13 | 0001615774-17-001665 | SEC ↗ |